<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Obes Metab</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Obes Metab</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1463-1326</journal-id><journal-id journal-id-type="publisher-id">DOM</journal-id><journal-title-group><journal-title>Diabetes, Obesity &#x00026; Metabolism</journal-title></journal-title-group><issn pub-type="ppub">1462-8902</issn><issn pub-type="epub">1463-1326</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27381275</article-id><article-id pub-id-type="pmc">5129465</article-id><article-id pub-id-type="doi">10.1111/dom.12736</article-id><article-id pub-id-type="publisher-id">DOM12736</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (<styled-content style="fixed-case">LIRA&#x02010;SWITCH</styled-content>): a randomized, double&#x02010;blind, double&#x02010;dummy, active&#x02010;controlled 26&#x02010;week trial</article-title><alt-title alt-title-type="right-running-head">B<sc>ailey et al.</sc></alt-title><alt-title alt-title-type="left-running-head">B<sc>ailey et al.</sc></alt-title></title-group><contrib-group><contrib id="dom12736-cr-0001" contrib-type="author" corresp="yes"><name><surname>Bailey</surname><given-names>T. S.</given-names></name><degrees>MD</degrees><address><email>tbailey@amcrinstitute.com</email></address><xref ref-type="aff" rid="dom12736-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom12736-cr-0002" contrib-type="author"><name><surname>Tak&#x000e1;cs</surname><given-names>R.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom12736-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom12736-cr-0003" contrib-type="author"><name><surname>Tinahones</surname><given-names>F. J.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom12736-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="dom12736-cr-0004" contrib-type="author"><name><surname>Rao</surname><given-names>P. V.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom12736-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="dom12736-cr-0005" contrib-type="author"><name><surname>Tsoukas</surname><given-names>G. M.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom12736-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="dom12736-cr-0006" contrib-type="author"><name><surname>Thomsen</surname><given-names>A. B.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom12736-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="dom12736-cr-0007" contrib-type="author"><name><surname>Kaltoft</surname><given-names>M. S.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom12736-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="dom12736-cr-0008" contrib-type="author"><name><surname>Maislos</surname><given-names>M.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom12736-aff-0007">
<sup>7</sup>
</xref></contrib></contrib-group><aff id="dom12736-aff-0001"><label><sup>1</sup></label><institution>AMCR Institute</institution><named-content content-type="city">Escondido</named-content><named-content content-type="country-part">California, USA</named-content></aff><aff id="dom12736-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">First Department of Medicine</named-content><institution>University of Szeged</institution><named-content content-type="city">Szeged</named-content><country country="HU">Hungary</country></aff><aff id="dom12736-aff-0003"><label><sup>3</sup></label><named-content content-type="organisation-division">Department of Clinical Endocrinology and Nutrition, IBIMA, Hospital Virgen de la Victoria, CIBERobn, Instituto de Salud Carlos III</named-content><institution>University of M&#x000e1;laga</institution><named-content content-type="city">M&#x000e1;laga</named-content><country country="ES">Spain</country></aff><aff id="dom12736-aff-0004"><label><sup>4</sup></label><named-content content-type="organisation-division">Kumudini Devi Diabetes Research Center</named-content><institution>Ramdevrao Hospital</institution><named-content content-type="city">Hyderabad</named-content><named-content content-type="country-part">Telangana</named-content><country country="IN">India</country></aff><aff id="dom12736-aff-0005"><label><sup>5</sup></label><named-content content-type="organisation-division">Department of Endocrinology and Metabolism</named-content><institution>McGill University Health Centre</institution><named-content content-type="city">Montreal</named-content><country country="CA">Canada</country></aff><aff id="dom12736-aff-0006"><label><sup>6</sup></label><named-content content-type="organisation-division">Global Development, Medical and Science, GLP&#x02010;1 and Obesity</named-content><institution>Novo Nordisk A/S</institution><named-content content-type="city">S&#x000f8;borg</named-content><country country="DK">Denmark</country></aff><aff id="dom12736-aff-0007"><label><sup>7</sup></label><named-content content-type="organisation-division">Atherosclerosis and Metabolism Unit, Soroka UMC</named-content><institution>Ben&#x02010;Gurion University FOHS</institution><named-content content-type="city">Be'er Sheva</named-content><country country="IL">Israel</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Corresponding Author</bold>: Timothy Bailey, MD, AMCR Institute Inc., 625 West Citracado Parkway, Suite 112, Escondido, CA 92025, USA (<email>tbailey@amcrinstitute.com</email>).</corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>9</month><year>2016</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2016</year></pub-date><volume>18</volume><issue>12</issue><issue-id pub-id-type="doi">10.1111/dom.2016.18.issue-12</issue-id><fpage>1191</fpage><lpage>1198</lpage><history><date date-type="received"><day>29</day><month>3</month><year>2016</year></date><date date-type="rev-recd"><day>01</day><month>7</month><year>2016</year></date><date date-type="accepted"><day>02</day><month>7</month><year>2016</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2016 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2016 The Authors. <italic>Diabetes, Obesity and Metabolism</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:DOM-18-1191.pdf"/><abstract id="dom12736-abs-0001"><sec id="dom12736-sec-0001"><title>Aims</title><p id="dom12736-para-0011">To confirm superiority on glycaemic control by switching from sitagliptin to liraglutide 1.8&#x02009;mg/d versus continued sitagliptin.</p></sec><sec id="dom12736-sec-0002"><title>Materials and methods</title><p id="dom12736-para-0012">A randomized, multicentre, double&#x02010;blind, double&#x02010;dummy, active&#x02010;controlled trial across 86 office&#x02010; or hospital&#x02010;based sites in <styled-content style="fixed-case">N</styled-content>orth <styled-content style="fixed-case">A</styled-content>merica, <styled-content style="fixed-case">E</styled-content>urope and <styled-content style="fixed-case">A</styled-content>sia. Subjects with type 2 diabetes who had inadequate glycaemic control (glycated haemoglobin [<styled-content style="fixed-case">HbA1c</styled-content>] 7.5&#x02212;9.5% on sitagliptin (100&#x02009;mg/d) and metformin (&#x02265;1500&#x02009;mg daily) for &#x02265;90&#x02009;days were randomized to either switch to liraglutide (n&#x02009;=&#x02009;203) or continue sitagliptin (n&#x02009;=&#x02009;204), both with metformin. The primary endpoint was change in <styled-content style="fixed-case">HbA1c</styled-content> from baseline to week 26. Change in body weight was a confirmatory secondary endpoint.</p></sec><sec id="dom12736-sec-0003"><title>Results</title><p id="dom12736-para-0013">Greater reduction in mean <styled-content style="fixed-case">HbA1c</styled-content> was achieved with liraglutide than with continued sitagliptin [&#x02212;1.14% vs. &#x02212;0.54%; estimated mean treatment difference (<styled-content style="fixed-case">ETD</styled-content>): &#x02212;0.61% (95% <styled-content style="fixed-case">CI</styled-content> &#x02212;0.82 to &#x02212;0.40; p&#x02009;&#x0003c;&#x02009;0.0001)], confirming superiority of switching to liraglutide. Body weight was reduced more with liraglutide [&#x02212;3.31&#x02009;kg vs. &#x02212;1.64&#x02009;kg; <styled-content style="fixed-case">ETD</styled-content>: &#x02212;1.67&#x02009;kg (95% <styled-content style="fixed-case">CI</styled-content> &#x02212;2.34 to &#x02212;0.99; p&#x02009;&#x0003c;&#x02009;0.0001)]. Nausea was more common with liraglutide [44 subjects (21.8%)] than with continued sitagliptin [16 (7.8%)]. Three subjects (1.5%) taking sitagliptin reported a confirmed hypoglycaemic episode.</p></sec><sec id="dom12736-sec-0004"><title>Conclusions</title><p id="dom12736-para-0014">Subjects insufficiently controlled with sitagliptin who switch to liraglutide can obtain clinically relevant reductions in glycaemia and body weight, without compromising safety. A switch from sitagliptin to liraglutide provides an option for improved management of type 2 diabetes while still allowing patients to remain on dual therapy.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="dom12754-kwd-0001">liraglutide</kwd><kwd id="dom12754-kwd-0002">sitagliptin</kwd><kwd id="dom12754-kwd-0003">type 2 diabetes</kwd><kwd id="dom12754-kwd-0004">GLP-1 receptor agonist</kwd></kwd-group><funding-group><award-group><funding-source>Novo Nordisk</funding-source></award-group></funding-group><counts><fig-count count="3"/><table-count count="2"/><page-count count="8"/><word-count count="5252"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>dom12736</meta-value></custom-meta><custom-meta><meta-name>header-id</meta-name><meta-value>dom12736-hdr-0001</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>December 2016</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.8 mode:remove_FC converted:24.11.2016</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="dom12736-cit-1001">
<string-name>
<surname>Bailey</surname>
<given-names>TS</given-names>
</string-name>, <string-name>
<surname>Tak&#x000e1;cs</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Tinahones</surname>
<given-names>FJ</given-names>
</string-name>, <string-name>
<surname>Rao</surname>
<given-names>PV</given-names>
</string-name>, <string-name>
<surname>Tsoukas</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Thomsen</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Kaltoft</surname>
<given-names>MS</given-names>
</string-name> and <string-name>
<surname>Maislos</surname>
<given-names>M</given-names>
</string-name>. <article-title>Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA&#x02010;SWITCH): a randomized, double&#x02010;blind, double&#x02010;dummy, active&#x02010;controlled 26&#x02010;week trial</article-title>, <source>Diabetes Obes Metab</source>
<year>2016</year>, <volume>18</volume>, <fpage>1191</fpage>&#x02013;<lpage>1198</lpage>. DOI:<ext-link ext-link-type="doi" xlink:href="10.1111/dom.12736">10.1111/dom.12736</ext-link>
<pub-id pub-id-type="pmid">27381275</pub-id></mixed-citation>
</p></notes></front><body><sec id="dom12736-sec-0005"><label>1</label><title>INTRODUCTION</title><p id="dom12736-para-0015">Hyperglycaemia management in type 2 diabetes (T2D) requires a patient&#x02010;centred approach, with therapy choice dependent on various patient&#x02010; and disease&#x02010;specific factors.<xref rid="dom12736-bib-0001" ref-type="ref">1</xref>, <xref rid="dom12736-bib-0002" ref-type="ref">2</xref> When diet and exercise are insufficient, patients are generally started on metformin, and when intensification is required, a second oral antidiabetic drug (OAD), injectable glucagon&#x02010;like peptide&#x02010;1 receptor agonists (GLP&#x02010;1RAs) or insulin, is equally recommended as second&#x02010;line therapy by the American Diabetes Association/European Association for the Study of Diabetes (ADA/EASD) position statement.<xref rid="dom12736-bib-0002" ref-type="ref">2</xref>
</p><p id="dom12736-para-0016">Liraglutide is a GLP&#x02010;1RA for treatment of T2D that offers effective glycaemic control, benefits in weight reduction, improved measures of &#x003b2;&#x02010;cell function (homeostatic model assessment of &#x003b2;&#x02010;cell function [HOMA&#x02010;B]) and a lower risk of hypoglycaemia than with insulin and selected OADs.<xref rid="dom12736-bib-0003" ref-type="ref">3</xref>, <xref rid="dom12736-bib-0004" ref-type="ref">4</xref> Sitagliptin is a dipeptidyl peptidase&#x02010;4 inhibitor (DPP&#x02010;4i), also shown to improve glycaemic control and HOMA&#x02010;B in patients with T2D.<xref rid="dom12736-bib-0005" ref-type="ref">5</xref>, <xref rid="dom12736-bib-0006" ref-type="ref">6</xref> DPP&#x02010;4is and GLP&#x02010;1RAs represent two different therapy classes; GLP&#x02010;1RAs promote GLP&#x02010;1 receptor signalling via stimulation through circulating &#x0201c;incretin mimetics&#x0201d;; DPP&#x02010;4is prevent degradation of endogenously released GLP&#x02010;1 in connection with meals.<xref rid="dom12736-bib-0007" ref-type="ref">7</xref> Whereas DPP&#x02010;4is may be associated with fewer gastrointestinal (GI) adverse events (AEs) than GLP&#x02010;1RAs, clinical trials have shown that GLP&#x02010;1RAs are superior to DPP&#x02010;4is regarding glycaemic control and body weight reduction when tested head&#x02010;to&#x02010;head.<xref rid="dom12736-bib-0008" ref-type="ref">8</xref>, <xref rid="dom12736-bib-0009" ref-type="ref">9</xref> However, limited clinical evidence exists to guide treatment strategy when initial second&#x02010;line treatment with sitagliptin fails to provide adequate glycaemic control.</p><p id="dom12736-para-0017">A previous head&#x02010;to&#x02010;head, open&#x02010;label, phase 4 clinical trial demonstrated that liraglutide 1.2&#x02009;mg and 1.8&#x02009;mg were superior to sitagliptin after 52 weeks regarding glycated haemoglobin (HbA1c) reduction, proportion of subjects reaching the ADA HbA1c target and body weight reduction.<xref rid="dom12736-bib-0010" ref-type="ref">10</xref> Furthermore, an extension of that trial demonstrated that switching subjects from sitagliptin to liraglutide 1.2&#x02009;mg and 1.8&#x02009;mg, respectively, after 52 weeks of treatment resulted in additional and statistically significant reduction in HbA1c at week 78. These latter extension data were obtained, however, without a formal control group.<xref rid="dom12736-bib-0011" ref-type="ref">11</xref>
</p><p id="dom12736-para-0018">Based on these previous open&#x02010;label, uncontrolled data, it was hypothesized that by switching insufficiently controlled subjects from metformin&#x02009;+&#x02009;sitagliptin to metformin&#x02009;+&#x02009;liraglutide, more patients with T2D would achieve better glycaemic control in terms of HbA1c reduction, with an associated reduction in body weight while still being on dual therapy. Accordingly, the primary objective of this trial was to confirm superiority on glycaemic control by switching from sitagliptin 100&#x02009;mg/d to liraglutide 1.8&#x02009;mg/d versus continued sitagliptin 100&#x02009;mg/d, in subjects on unchanged metformin therapy. Secondary objectives were to compare effects of switching from sitagliptin to liraglutide (vs. continued sitagliptin) on body weight, selected cardiovascular risk factors, safety and tolerability. Results of this trial would be expected to further inform clinical decision&#x02010;making for patients with T2D.</p></sec><sec id="dom12736-sec-0006"><label>2</label><title>RESEARCH DESIGN AND METHODS</title><sec id="dom12736-sec-0007"><label>2.1</label><title>Participants</title><p id="dom12736-para-0019">Inclusion criteria were: T2D, age &#x02265;18&#x02009;years, HbA1c 7.5&#x02212;9.5%, body mass index (BMI) &#x02265;20&#x02009;kg/m<sup>2</sup>, previous treatment with stable doses of sitagliptin (100&#x02009;mg/d) and metformin [&#x02265;1500&#x02009;mg/d or maximum tolerated dose (MTD) &#x02265;1000&#x02009;mg/d] for &#x02265;90&#x02009;days. See Appendix S1 for exclusion criteria.</p><p id="dom12736-para-0020">The study was conducted in accordance with the Declaration of Helsinki,<xref rid="dom12736-bib-0012" ref-type="ref">12</xref> good clinical practice guidelines<xref rid="dom12736-bib-0013" ref-type="ref">13</xref> and was approved by independent ethics committees. Informed consent was obtained before any trial&#x02010;related activity.</p></sec><sec id="dom12736-sec-0008"><label>2.2</label><title>Study design</title><p id="dom12736-para-0021">This trial (LIRA&#x02010;SWITCH) was a phase 4, 26&#x02010;week, randomized, multicentre, parallel&#x02010;group, double&#x02010;blind, double&#x02010;dummy, active&#x02010;controlled trial conducted across 86 office&#x02010; or hospital&#x02010;based sites in the USA, Canada, Hungary, Israel, India and Spain between December 2013 and June 2015. A total of 407 subjects were randomized 1:1 to one of two study arms (using interactive voice/web response system [IV/WRS]): liraglutide (subcutaneously) at a starting dose of 0.6&#x02009;mg/d, with weekly dose escalations of 0.6&#x02009;mg/d until the maintenance dose of 1.8&#x02009;mg/d was reached, plus once&#x02010;daily sitagliptin placebo tablets versus oral sitagliptin tablets (100&#x02009;mg/d) plus liraglutide placebo (subcutaneously) mirroring dose escalation of the active liraglutide arm. Both arms continued metformin at pre&#x02010;trial dose. Subjects were stratified according to baseline HbA1c (&#x02264;8.5% and &#x0003e;8.5%) and metformin dose (&#x0003c;1500 and &#x02265;1500&#x02009;mg/d). After randomization, a 26&#x02010;week treatment period was completed, followed by a 1&#x02010;week follow&#x02010;up period.</p><p id="dom12736-para-0022">For subjects meeting predefined hyperglycaemia criteria, predefined criteria for discontinuation of trial products or withdrawal from the trial, protocol amendments, and method of assigning subjects to treatments, please see Appendices S2&#x02013;S5.</p></sec><sec id="dom12736-sec-0009"><label>2.3</label><title>Study measurements</title><sec id="dom12736-sec-0010"><label>2.3.1</label><title>Efficacy</title><p id="dom12736-para-0023">The primary endpoint was change in HbA1c from baseline to week 26. A confirmatory secondary endpoint was change in body weight from baseline to week 26. Other secondary endpoints included: change in fasting plasma glucose (FPG); change in systolic (SBP) and diastolic blood pressure (DBP) and change in fasting blood lipid levels; subjects meeting HbA1c targets &#x0003c;7.0% (ADA target) and &#x02264;6.5% (American Association of Clinical Endocrinologists target); composite endpoints including subjects achieving HbA1c reduction of &#x02265;1.0% and no weight gain; HbA1c &#x0003c;7.0% and no weight gain; HbA1c &#x0003c;7.0%, no weight gain and SBP &#x0003c;140&#x02009;mm Hg.</p></sec><sec id="dom12736-sec-0011"><label>2.3.2</label><title>Safety</title><p id="dom12736-para-0024">Safety endpoints included the number of treatment&#x02010;emergent adverse events (TEAEs), hypoglycaemic episodes during trial treatment (confirmed and ADA&#x02010;classified episodes; see Table <xref rid="dom12736-tbl-0001" ref-type="table-wrap">1</xref> for definitions), changes in haematological and biochemical laboratory parameters (including lipase and amylase) and change in pulse.</p><table-wrap id="dom12736-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Summary of treatment&#x02010;emergent adverse events and hypoglycaemic episodes with liraglutide or sitagliptin</p></caption><table frame="hsides" rules="groups"><col width="1*" align="left" span="1"/><col width="1*" align="char" char="(" span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="(" span="1"/><col width="1*" align="char" char="." span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" id="dom12736-ent-0001" align="left" valign="bottom" colspan="1"/><th colspan="2" id="dom12736-ent-0002" align="char" valign="bottom" rowspan="1">
<bold>Liraglutide</bold>
</th><th colspan="2" id="dom12736-ent-0003" align="char" valign="bottom" rowspan="1">
<bold>Sitagliptin</bold>
</th></tr><tr style="border-bottom:solid 1px #000000"><th id="dom12736-ent-0005" align="char" valign="bottom" rowspan="1" colspan="1">
<bold>N (%)</bold>
</th><th id="dom12736-ent-0006" align="char" valign="bottom" rowspan="1" colspan="1">E</th><th id="dom12736-ent-0007" align="char" valign="bottom" rowspan="1" colspan="1">
<bold>N (%)</bold>
</th><th id="dom12736-ent-0008" align="char" valign="bottom" rowspan="1" colspan="1">E</th></tr></thead><tbody valign="top"><tr><td id="dom12736-ent-0009" align="left" valign="top" rowspan="1" colspan="1">
<bold>Number of subjects</bold>
</td><td id="dom12736-ent-0010" align="char" valign="top" rowspan="1" colspan="1">202 (100)</td><td id="dom12736-ent-0011" align="char" valign="top" rowspan="1" colspan="1"/><td id="dom12736-ent-0012" align="char" valign="top" rowspan="1" colspan="1">204 (100)</td><td id="dom12736-ent-0013" align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td id="dom12736-ent-0014" align="left" valign="top" rowspan="1" colspan="1">
<bold>Total AEs</bold>
</td><td id="dom12736-ent-0015" align="char" valign="top" rowspan="1" colspan="1">139 (68.8)</td><td id="dom12736-ent-0016" align="char" valign="top" rowspan="1" colspan="1">455</td><td id="dom12736-ent-0017" align="char" valign="top" rowspan="1" colspan="1">116 (56.9)</td><td id="dom12736-ent-0018" align="char" valign="top" rowspan="1" colspan="1">318</td></tr><tr><td id="dom12736-ent-0019" align="left" valign="top" rowspan="1" colspan="1">
<bold>Serious AEs</bold>
</td><td id="dom12736-ent-0020" align="char" valign="top" rowspan="1" colspan="1">6 (3.0)</td><td id="dom12736-ent-0021" align="char" valign="top" rowspan="1" colspan="1">8</td><td id="dom12736-ent-0022" align="char" valign="top" rowspan="1" colspan="1">7 (3.4)</td><td id="dom12736-ent-0023" align="char" valign="top" rowspan="1" colspan="1">8</td></tr><tr><td colspan="5" id="dom12736-ent-0024" align="left" valign="top" rowspan="1">
<bold>Most common AEs (&#x02265;5% by preferred term)</bold>
</td></tr><tr><td style="padding-left:10%" id="dom12736-ent-0025" align="left" valign="top" rowspan="1" colspan="1">Nausea</td><td id="dom12736-ent-0026" align="char" valign="top" rowspan="1" colspan="1">44 (21.8)</td><td id="dom12736-ent-0027" align="char" valign="top" rowspan="1" colspan="1">59</td><td id="dom12736-ent-0028" align="char" valign="top" rowspan="1" colspan="1">16 (7.8)</td><td id="dom12736-ent-0029" align="char" valign="top" rowspan="1" colspan="1">21</td></tr><tr><td style="padding-left:10%" id="dom12736-ent-0030" align="left" valign="top" rowspan="1" colspan="1">Diarrhoea</td><td id="dom12736-ent-0031" align="char" valign="top" rowspan="1" colspan="1">33 (16.3)</td><td id="dom12736-ent-0032" align="char" valign="top" rowspan="1" colspan="1">45</td><td id="dom12736-ent-0033" align="char" valign="top" rowspan="1" colspan="1">19 (9.3)</td><td id="dom12736-ent-0034" align="char" valign="top" rowspan="1" colspan="1">21</td></tr><tr><td style="padding-left:10%" id="dom12736-ent-0035" align="left" valign="top" rowspan="1" colspan="1">Decreased appetite</td><td id="dom12736-ent-0036" align="char" valign="top" rowspan="1" colspan="1">18 (8.9)</td><td id="dom12736-ent-0037" align="char" valign="top" rowspan="1" colspan="1">18</td><td id="dom12736-ent-0038" align="char" valign="top" rowspan="1" colspan="1">7 (3.4)</td><td id="dom12736-ent-0039" align="char" valign="top" rowspan="1" colspan="1">7</td></tr><tr><td style="padding-left:10%" id="dom12736-ent-0040" align="left" valign="top" rowspan="1" colspan="1">Vomiting</td><td id="dom12736-ent-0041" align="char" valign="top" rowspan="1" colspan="1">15 (7.4)</td><td id="dom12736-ent-0042" align="char" valign="top" rowspan="1" colspan="1">18</td><td id="dom12736-ent-0043" align="char" valign="top" rowspan="1" colspan="1">10 (4.9)</td><td id="dom12736-ent-0044" align="char" valign="top" rowspan="1" colspan="1">15</td></tr><tr><td style="padding-left:10%" id="dom12736-ent-0045" align="left" valign="top" rowspan="1" colspan="1">Headache</td><td id="dom12736-ent-0046" align="char" valign="top" rowspan="1" colspan="1">13 (6.4)</td><td id="dom12736-ent-0047" align="char" valign="top" rowspan="1" colspan="1">16</td><td id="dom12736-ent-0048" align="char" valign="top" rowspan="1" colspan="1">12 (5.9)</td><td id="dom12736-ent-0049" align="char" valign="top" rowspan="1" colspan="1">16</td></tr><tr><td style="padding-left:10%" id="dom12736-ent-0050" align="left" valign="top" rowspan="1" colspan="1">Nasopharyngitis</td><td id="dom12736-ent-0051" align="char" valign="top" rowspan="1" colspan="1">12 (5.9)</td><td id="dom12736-ent-0052" align="char" valign="top" rowspan="1" colspan="1">14</td><td id="dom12736-ent-0053" align="char" valign="top" rowspan="1" colspan="1">7 (3.4)</td><td id="dom12736-ent-0054" align="char" valign="top" rowspan="1" colspan="1">7</td></tr><tr><td style="padding-left:10%" id="dom12736-ent-0055" align="left" valign="top" rowspan="1" colspan="1">Lipase increased</td><td id="dom12736-ent-0056" align="char" valign="top" rowspan="1" colspan="1">11 (5.5)</td><td id="dom12736-ent-0057" align="char" valign="top" rowspan="1" colspan="1">12</td><td id="dom12736-ent-0058" align="char" valign="top" rowspan="1" colspan="1">9 (4.4)</td><td id="dom12736-ent-0059" align="char" valign="top" rowspan="1" colspan="1">9</td></tr><tr><td style="padding-left:10%" id="dom12736-ent-0060" align="left" valign="top" rowspan="1" colspan="1">Amylase increased</td><td id="dom12736-ent-0061" align="char" valign="top" rowspan="1" colspan="1">4 (2.0)</td><td id="dom12736-ent-0062" align="char" valign="top" rowspan="1" colspan="1">4</td><td id="dom12736-ent-0063" align="char" valign="top" rowspan="1" colspan="1">4 (2.0)</td><td id="dom12736-ent-0064" align="char" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td colspan="5" id="dom12736-ent-0065" align="left" valign="top" rowspan="1">
<bold>Hypoglycaemic episodes</bold>
</td></tr><tr><td style="padding-left:10%" id="dom12736-ent-0066" align="left" valign="top" rowspan="1" colspan="1">Confirmed</td><td id="dom12736-ent-0067" align="char" valign="top" rowspan="1" colspan="1">0</td><td id="dom12736-ent-0068" align="char" valign="top" rowspan="1" colspan="1"/><td id="dom12736-ent-0069" align="char" valign="top" rowspan="1" colspan="1">3 (1.5)</td><td id="dom12736-ent-0070" align="char" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td style="padding-left:10%" id="dom12736-ent-0071" align="left" valign="top" rowspan="1" colspan="1">ADA classification</td><td id="dom12736-ent-0072" align="char" valign="top" rowspan="1" colspan="1"/><td id="dom12736-ent-0073" align="char" valign="top" rowspan="1" colspan="1"/><td id="dom12736-ent-0074" align="char" valign="top" rowspan="1" colspan="1"/><td id="dom12736-ent-0075" align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" id="dom12736-ent-0076" align="left" valign="top" rowspan="1" colspan="1">Severe</td><td id="dom12736-ent-0077" align="char" valign="top" rowspan="1" colspan="1">0</td><td id="dom12736-ent-0078" align="char" valign="top" rowspan="1" colspan="1"/><td id="dom12736-ent-0079" align="char" valign="top" rowspan="1" colspan="1">0</td><td id="dom12736-ent-0080" align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" id="dom12736-ent-0081" align="left" valign="top" rowspan="1" colspan="1">Documented symptomatic</td><td id="dom12736-ent-0082" align="char" valign="top" rowspan="1" colspan="1">3 (1.5)</td><td id="dom12736-ent-0083" align="char" valign="top" rowspan="1" colspan="1">4</td><td id="dom12736-ent-0084" align="char" valign="top" rowspan="1" colspan="1">3 (1.5)</td><td id="dom12736-ent-0085" align="char" valign="top" rowspan="1" colspan="1">6</td></tr><tr><td style="padding-left:10%" id="dom12736-ent-0086" align="left" valign="top" rowspan="1" colspan="1">Asymptomatic</td><td id="dom12736-ent-0087" align="char" valign="top" rowspan="1" colspan="1">5 (2.5)</td><td id="dom12736-ent-0088" align="char" valign="top" rowspan="1" colspan="1">5</td><td id="dom12736-ent-0089" align="char" valign="top" rowspan="1" colspan="1">5 (2.5)</td><td id="dom12736-ent-0090" align="char" valign="top" rowspan="1" colspan="1">13</td></tr><tr><td style="padding-left:10%" id="dom12736-ent-0091" align="left" valign="top" rowspan="1" colspan="1">Probable symptomatic</td><td id="dom12736-ent-0092" align="char" valign="top" rowspan="1" colspan="1">1 (0.5)</td><td id="dom12736-ent-0093" align="char" valign="top" rowspan="1" colspan="1">2</td><td id="dom12736-ent-0094" align="char" valign="top" rowspan="1" colspan="1">1 (0.5)</td><td id="dom12736-ent-0095" align="char" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td style="padding-left:10%" id="dom12736-ent-0096" align="left" valign="top" rowspan="1" colspan="1">Relative</td><td id="dom12736-ent-0097" align="char" valign="top" rowspan="1" colspan="1">3 (1.5)</td><td id="dom12736-ent-0098" align="char" valign="top" rowspan="1" colspan="1">3</td><td id="dom12736-ent-0099" align="char" valign="top" rowspan="1" colspan="1">0</td><td id="dom12736-ent-0100" align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" id="dom12736-ent-0101" align="left" valign="top" rowspan="1" colspan="1">Unclassified</td><td id="dom12736-ent-0102" align="char" valign="top" rowspan="1" colspan="1">0</td><td id="dom12736-ent-0103" align="char" valign="top" rowspan="1" colspan="1">0</td><td id="dom12736-ent-0104" align="char" valign="top" rowspan="1" colspan="1">0</td><td id="dom12736-ent-0105" align="char" valign="top" rowspan="1" colspan="1">0</td></tr></tbody></table><table-wrap-foot><fn id="dom12736-note-0001"><p>Confirmed hypoglycaemic episode: patients unable to treat themselves (severe hypoglycaemic episode) and/or with a plasma glucose reading &#x0003c;3.1&#x02009;mmol/<styled-content style="fixed-case">L</styled-content> (56&#x02009;mg/d<styled-content style="fixed-case">L</styled-content>).</p></fn><fn id="dom12736-note-0002"><p>%, percentage of subjects experiencing at least one event; <styled-content style="fixed-case">ADA</styled-content>, <styled-content style="fixed-case">A</styled-content>merican <styled-content style="fixed-case">D</styled-content>iabetes <styled-content style="fixed-case">A</styled-content>ssociation; <styled-content style="fixed-case">AE</styled-content>, adverse event; <styled-content style="fixed-case">E</styled-content>, number of events (except for where number of hypoglycaemic episodes); <styled-content style="fixed-case">N</styled-content>, number of subjects experiencing at least one event.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="dom12736-sec-0012"><label>2.4</label><title>Statistical analysis</title><p id="dom12736-para-0025">The sample size, based on the test of the treatment difference in change from baseline in HbA1c after 26&#x02009;weeks, was determined to be able to detect, with a 90% probability, a mean difference of 0.4% for liraglutide vs. sitagliptin, at a 5% significance level. Efficacy endpoints were assessed using the full analysis set (FAS), including all randomized subjects receiving at least one dose of any of the trial products. The statistical evaluation of the FAS followed the intention&#x02010;to&#x02010;treat (ITT) principle. Safety endpoints were assessed using the safety analysis set (SAS), including all subjects receiving at least one dose of any of the trial products. Subjects in the safety set contributed to the evaluation &#x0201c;as treated&#x0201d;. Data collected after subjects initiated rescue treatment or discontinued trial medication were considered as missing in all analyses.</p><p id="dom12736-para-0026">The primary endpoint, confirmatory secondary endpoint and other continuous secondary endpoints were analysed with the mixed model for repeated measurements (MMRM). If superiority was confirmed for the primary endpoint, the confirmatory secondary endpoint (change in body weight) was to be tested for superiority of liraglutide over sitagliptin. For the primary and secondary confirmatory endpoints, the MMRM included treatment, baseline HbA1c level, metformin dose, the interaction between baseline HbA<sub>1c</sub> level and metformin dose and country as factors, and the value of the response variable at baseline as a covariate, all variables nested within week as a factor. An unstructured covariance matrix was used to describe the variability for the repeated measurements for a subject.</p><p id="dom12736-para-0027">Dichotomous endpoints were analysed by a logistic regression model. Effects in the model were treatment, baseline HbA1c level (&#x02264;8.5% and &#x0003e;8.5%), metformin dose (&#x0003c;1500 and &#x02265;1500&#x02009;mg/d), the interaction between baseline HbA1c level and metformin dose and country as factors, and baseline HbA1c as a covariate.</p><p id="dom12736-para-0028">All safety endpoints were summarized descriptively using the SAS. Continuous safety endpoints were analysed by a method similar to that of the primary analysis. The significance level was set at 5% (two&#x02010;sided tests).</p></sec></sec><sec id="dom12736-sec-0013"><label>3</label><title>RESULTS</title><sec id="dom12736-sec-0014"><label>3.1</label><title>Baseline characteristics and subject disposition</title><p id="dom12736-para-0029">Study arms were well matched for demographic and other characteristics at baseline (Table <xref rid="dom12736-tbl-0002" ref-type="table-wrap">2</xref>).</p><table-wrap id="dom12736-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Baseline characteristics of subjects randomized to either liraglutide or sitagliptin</p></caption><table frame="hsides" rules="groups"><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" id="dom12736-ent-0106" valign="bottom" rowspan="1" colspan="1"/><th align="left" id="dom12736-ent-0107" valign="bottom" rowspan="1" colspan="1">
<bold>Liraglutide</bold>
</th><th align="left" id="dom12736-ent-0108" valign="bottom" rowspan="1" colspan="1">
<bold>Sitagliptin</bold>
</th></tr></thead><tbody valign="top"><tr><td align="left" id="dom12736-ent-0109" valign="top" rowspan="1" colspan="1">Safety analysis set, N</td><td align="left" id="dom12736-ent-0110" valign="top" rowspan="1" colspan="1">202</td><td align="left" id="dom12736-ent-0111" valign="top" rowspan="1" colspan="1">204</td></tr><tr><td align="left" id="dom12736-ent-0112" valign="top" rowspan="1" colspan="1">Age, years</td><td align="left" id="dom12736-ent-0113" valign="top" rowspan="1" colspan="1">56.3 (10.6)</td><td align="left" id="dom12736-ent-0114" valign="top" rowspan="1" colspan="1">56.5 (9.7)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12736-ent-0115" valign="top" rowspan="1" colspan="1">Range</td><td align="left" id="dom12736-ent-0116" valign="top" rowspan="1" colspan="1">28.0&#x02010;86.0</td><td align="left" id="dom12736-ent-0117" valign="top" rowspan="1" colspan="1">26.0&#x02010;83.0</td></tr><tr><td align="left" id="dom12736-ent-0118" valign="top" rowspan="1" colspan="1">Duration of diabetes, years</td><td align="left" id="dom12736-ent-0119" valign="top" rowspan="1" colspan="1">7.9 (5.7)</td><td align="left" id="dom12736-ent-0120" valign="top" rowspan="1" colspan="1">7.6 (6.2)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12736-ent-0121" valign="top" rowspan="1" colspan="1">Range</td><td align="left" id="dom12736-ent-0122" valign="top" rowspan="1" colspan="1">0.3&#x02010;33.3</td><td align="left" id="dom12736-ent-0123" valign="top" rowspan="1" colspan="1">0.3&#x02010;34.3</td></tr><tr><td align="left" id="dom12736-ent-0124" valign="top" rowspan="1" colspan="1">Female; Male (%)</td><td align="left" id="dom12736-ent-0125" valign="top" rowspan="1" colspan="1">42%; 58%</td><td align="left" id="dom12736-ent-0126" valign="top" rowspan="1" colspan="1">39%; 61%</td></tr><tr><td align="left" id="dom12736-ent-0127" valign="top" rowspan="1" colspan="1">Weight, kg</td><td align="left" id="dom12736-ent-0128" valign="top" rowspan="1" colspan="1">88.9 (19.8)</td><td align="left" id="dom12736-ent-0129" valign="top" rowspan="1" colspan="1">91.2 (19.6)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12736-ent-0130" valign="top" rowspan="1" colspan="1">Range</td><td align="left" id="dom12736-ent-0131" valign="top" rowspan="1" colspan="1">53.0&#x02010;173.9</td><td align="left" id="dom12736-ent-0132" valign="top" rowspan="1" colspan="1">46.5&#x02010;167.8</td></tr><tr><td align="left" id="dom12736-ent-0133" valign="top" rowspan="1" colspan="1">Height, m</td><td align="left" id="dom12736-ent-0134" valign="top" rowspan="1" colspan="1">1.67 (0.10)</td><td align="left" id="dom12736-ent-0135" valign="top" rowspan="1" colspan="1">1.68 (0.10)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12736-ent-0136" valign="top" rowspan="1" colspan="1">Range</td><td align="left" id="dom12736-ent-0137" valign="top" rowspan="1" colspan="1">1.43&#x02010;1.95</td><td align="left" id="dom12736-ent-0138" valign="top" rowspan="1" colspan="1">1.42&#x02010;1.91</td></tr><tr><td align="left" id="dom12736-ent-0139" valign="top" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>
</td><td align="left" id="dom12736-ent-0140" valign="top" rowspan="1" colspan="1">31.7 (6.0)</td><td align="left" id="dom12736-ent-0141" valign="top" rowspan="1" colspan="1">32.2 (6.2)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12736-ent-0142" valign="top" rowspan="1" colspan="1">Range</td><td align="left" id="dom12736-ent-0143" valign="top" rowspan="1" colspan="1">20.0&#x02010;55.0</td><td align="left" id="dom12736-ent-0144" valign="top" rowspan="1" colspan="1">20.2&#x02010;58.1</td></tr><tr><td align="left" id="dom12736-ent-0145" valign="top" rowspan="1" colspan="1">Waist circumference, cm</td><td align="left" id="dom12736-ent-0146" valign="top" rowspan="1" colspan="1">106.9 (14.8)</td><td align="left" id="dom12736-ent-0147" valign="top" rowspan="1" colspan="1">106.9 (14.4)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12736-ent-0148" valign="top" rowspan="1" colspan="1">Range</td><td align="left" id="dom12736-ent-0149" valign="top" rowspan="1" colspan="1">66.0&#x02010;168.7</td><td align="left" id="dom12736-ent-0150" valign="top" rowspan="1" colspan="1">68.6&#x02010;153.5</td></tr><tr><td align="left" id="dom12736-ent-0151" valign="top" rowspan="1" colspan="1">FPG, mmol/L [mg/dL]</td><td align="left" id="dom12736-ent-0152" valign="top" rowspan="1" colspan="1">10.0 (181) [2.7 (48.1)]</td><td align="left" id="dom12736-ent-0153" valign="top" rowspan="1" colspan="1">9.7 (174.1) [2.5([44.5)]</td></tr><tr><td align="left" style="padding-left:10%" id="dom12736-ent-0154" valign="top" rowspan="1" colspan="1">Range</td><td align="left" id="dom12736-ent-0155" valign="top" rowspan="1" colspan="1">3.8&#x02010;21.8 (68.5&#x02010;392.8)</td><td align="left" id="dom12736-ent-0156" valign="top" rowspan="1" colspan="1">4.5&#x02010;19.2 (81.1&#x02010;346.0)</td></tr><tr><td align="left" id="dom12736-ent-0157" valign="top" rowspan="1" colspan="1">HbA1c, % [mmol/mol]</td><td align="left" id="dom12736-ent-0158" valign="top" rowspan="1" colspan="1">8.3 (67) [0.6 (7)]</td><td align="left" id="dom12736-ent-0159" valign="top" rowspan="1" colspan="1">8.2 (67) [0.6 (7)]</td></tr><tr><td align="left" style="padding-left:10%" id="dom12736-ent-0160" valign="top" rowspan="1" colspan="1">Range</td><td align="left" id="dom12736-ent-0161" valign="top" rowspan="1" colspan="1">(6.3&#x02010;10.7)</td><td align="left" id="dom12736-ent-0162" valign="top" rowspan="1" colspan="1">(5.7&#x02010;10.1)</td></tr><tr><td align="left" id="dom12736-ent-0163" valign="top" rowspan="1" colspan="1">Systolic blood pressure, mm Hg</td><td align="left" id="dom12736-ent-0164" valign="top" rowspan="1" colspan="1">130.5 (14.4)</td><td align="left" id="dom12736-ent-0165" valign="top" rowspan="1" colspan="1">132.1 (12.1)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12736-ent-0166" valign="top" rowspan="1" colspan="1">Range</td><td align="left" id="dom12736-ent-0167" valign="top" rowspan="1" colspan="1">99.0&#x02010;178.0</td><td align="left" id="dom12736-ent-0168" valign="top" rowspan="1" colspan="1">96.0&#x02010;171.0</td></tr><tr><td align="left" id="dom12736-ent-0169" valign="top" rowspan="1" colspan="1">Diastolic blood pressure, mm Hg</td><td align="left" id="dom12736-ent-0170" valign="top" rowspan="1" colspan="1">79.0 (8.1)</td><td align="left" id="dom12736-ent-0171" valign="top" rowspan="1" colspan="1">78.9 (7.6)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12736-ent-0172" valign="top" rowspan="1" colspan="1">Range</td><td align="left" id="dom12736-ent-0173" valign="top" rowspan="1" colspan="1">49.0&#x02010;98.0</td><td align="left" id="dom12736-ent-0174" valign="top" rowspan="1" colspan="1">50.0&#x02010;96.0</td></tr></tbody></table><table-wrap-foot><fn id="dom12736-note-0003"><p>Mean (<styled-content style="fixed-case">SD</styled-content>) if not otherwise stated. <styled-content style="fixed-case">BMI</styled-content>, body mass index; <styled-content style="fixed-case">FPG</styled-content>, fasting plasma glucose; <styled-content style="fixed-case">HbA1c</styled-content>, glycated haemoglobin; <styled-content style="fixed-case">SD</styled-content>, standard deviation.</p></fn></table-wrap-foot></table-wrap><p id="dom12736-para-0030">Of the 814 subjects screened, 407 were randomized and 406 were exposed to trial medication. The trial was completed without treatment discontinuation or rescue medication by 159 (78.3%) subjects taking liraglutide and 157 (77%) taking sitagliptin. Rescue medication was required, respectively, by 11 (5.4%, liraglutide) and 30 subjects (14.7%, sitagliptin). More subjects prematurely discontinued liraglutide (21 subjects, 10.3%) than sitagliptin (8 subjects, 3.9%) (Figure <xref rid="dom12736-fig-0001" ref-type="fig">1</xref>). GI AEs leading to treatment discontinuation were only in the liraglutide group (9 subjects, 4.5%). To avoid missing data, subjects were encouraged to remain in the trial and complete end&#x02010;of&#x02010;trial and follow&#x02010;up visits even after permanently discontinuing trial product.</p><fig fig-type="Figure" xml:lang="en" id="dom12736-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Flow of subjects through the study. *Without treatment discontinuation or rescue medication. <sup>&#x02020;</sup>Two subjects in the liraglutide group and one in the sitagliptin group had the trial product discontinued and were thereafter withdrawn. <sup>&#x02021;</sup>One subject in the sitagliptin group received rescue treatment and was thereafter withdrawn. <styled-content style="fixed-case">FAS</styled-content> and <styled-content style="fixed-case">SAS</styled-content> include all randomized subjects receiving at least one dose of any of the trial products. <styled-content style="fixed-case">FAS</styled-content>, full analysis set; <styled-content style="fixed-case">SAS</styled-content>, safety analysis set.</p></caption><graphic id="nlm-graphic-1" xlink:href="DOM-18-1191-g003"/></fig></sec><sec id="dom12736-sec-0015"><label>3.2</label><title>Primary efficacy assessments</title><sec id="dom12736-sec-0016"><label>3.2.1</label><title>Change in <styled-content style="fixed-case">HbA1c</styled-content>
</title><p id="dom12736-para-0031">Switching from sitagliptin to liraglutide led to greater reduction in HbA1c versus continuing sitagliptin (ETD &#x02212;0.61%, &#x02212;1.14% vs. &#x02212;0.54%; 95% CI &#x02212;0.82 to &#x02212;0.40; p&#x02009;&#x0003c;&#x02009;0.0001), thus confirming the superiority of liraglutide (Figure <xref rid="dom12736-fig-0002" ref-type="fig">2</xref>A).</p><fig fig-type="Figure" xml:lang="en" id="dom12736-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Mean change in <styled-content style="fixed-case">HbA1c</styled-content> (<styled-content style="fixed-case">A</styled-content>), body weight (<styled-content style="fixed-case">B</styled-content>) and <styled-content style="fixed-case">FPG</styled-content> (<styled-content style="fixed-case">C</styled-content>) from baseline after 26&#x02009;weeks of treatment. On&#x02010;treatment summary without rescue data. Group mean estimates (&#x000b1; <styled-content style="fixed-case">SEM</styled-content>) are from a mixed model for repeat measurements (<styled-content style="fixed-case">MMRM</styled-content>) with treatment, strata, country and baseline value, all nested within visit, and are adjusted according to observed baseline distribution. <styled-content style="fixed-case">ETD</styled-content>, estimated treatment difference; <styled-content style="fixed-case">FPG</styled-content>, fasting plasma glucose; <styled-content style="fixed-case">HbA1c</styled-content>, glycated haemoglobin; <styled-content style="fixed-case">SEM</styled-content>, standard error of the mean.</p></caption><graphic id="nlm-graphic-3" xlink:href="DOM-18-1191-g001"/></fig></sec></sec><sec id="dom12736-sec-0017"><label>3.3</label><title>Confirmatory secondary endpoint</title><sec id="dom12736-sec-0018"><label>3.3.1</label><title>Change in body weight</title><p id="dom12736-para-0032">Significantly greater weight loss with liraglutide was observed compared with sitagliptin (ETD &#x02212;1.67&#x02009;kg, &#x02212;3.31&#x02009;kg vs. &#x02212;1.64&#x02009;kg; 95% CI &#x02212;2.34 to &#x02212;0.99; p&#x02009;&#x0003c;&#x02009;0.0001) (Figure <xref rid="dom12736-fig-0002" ref-type="fig">2</xref>B). Superiority of liraglutide over sitagliptin on body weight reduction was confirmed by hierarchical testing after the primary endpoint.</p></sec></sec><sec id="dom12736-sec-0019"><label>3.4</label><title>Secondary efficacy assessments</title><sec id="dom12736-sec-0020"><label>3.4.1</label><title>Fasting plasma glucose</title><p id="dom12736-para-0033">FPG decreased significantly more with liraglutide than with sitagliptin (ETD &#x02212;1.10&#x02009;mmol/L, &#x02212;1.84&#x02009;mmol/L vs. &#x02212;0.73&#x02009;mmol/L; 95% CI &#x02212;1.50 to &#x02212;0.71; p&#x02009;&#x0003c;&#x02009;0.0001) (Figure <xref rid="dom12736-fig-0002" ref-type="fig">2</xref>C).</p></sec><sec id="dom12736-sec-0021"><label>3.4.2</label><title>Change in blood pressure</title><p id="dom12736-para-0034">SBP change was not significantly different with liraglutide versus sitagliptin after 26&#x02009;weeks of treatment: &#x02212;4.05 versus &#x02212;2.18&#x02009;mm Hg; ETD &#x02212;1.87 (95% CI &#x02212;4.28 to 0.53, p&#x02009;=&#x02009;0.1264). Change in DBP was not significantly different comparing liraglutide with sitagliptin: &#x02212;0.27 versus &#x02212;0.68&#x02009;mm Hg; ETD 0.41 (95% CI &#x02212;1.02 to 1.85, p&#x02009;=&#x02009;0.5730).</p></sec><sec id="dom12736-sec-0022"><label>3.4.3</label><title>Fasting blood lipids</title><p id="dom12736-para-0035">Minor changes in lipid parameters were observed for both liraglutide and sitagliptin. There was no difference in fasting blood lipids at week 26 between the two treatments (Figure S1).</p></sec><sec id="dom12736-sec-0023"><label>3.4.4</label><title>Percentage of subjects reaching <styled-content style="fixed-case">HbA1c</styled-content> &#x0003c;7.0% and &#x02264;6.5%</title><p id="dom12736-para-0036">After 26&#x02009;weeks, a significantly higher proportion of subjects achieved HbA1c targets of &#x0003c;7.0% and &#x02264;6.5% with liraglutide than with sitagliptin. Proportions of subjects achieving the target of &#x0003c;7.0% were: 50.6% versus 26.9% with liraglutide and sitagliptin, respectively, odds ratio (OR): 3.36 (95% CI 2.08&#x02010;5.42, p&#x02009;&#x0003c;&#x02009;0.0001). Proportions achieving the target of &#x02264;6.5% were: 29.5% versus 9.9% with liraglutide and sitagliptin, respectively, OR: 5.44 (95% CI 2.82&#x02010;10.47, p&#x02009;&#x0003c;&#x02009;0.0001) (Figure <xref rid="dom12736-fig-0003" ref-type="fig">3</xref>).</p><fig fig-type="Figure" xml:lang="en" id="dom12736-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Subjects meeting <styled-content style="fixed-case">HbA1c</styled-content> targets for (<styled-content style="fixed-case">A</styled-content>) <styled-content style="fixed-case">ADA</styled-content> and (<styled-content style="fixed-case">B</styled-content>) <styled-content style="fixed-case">AACE</styled-content> after 26&#x02009;weeks of treatment. On&#x02010;treatment without rescue data with mixed model for repeated measurement (<styled-content style="fixed-case">MMRM</styled-content>) imputation: subjects meeting targets (%) and estimated odds ratio based on logistic regression model with treatment, strata, metformin dose and country as fixed factors and the <styled-content style="fixed-case">HbA1c</styled-content> value at baseline as a covariate. <styled-content style="fixed-case">AACE</styled-content>, <styled-content style="fixed-case">A</styled-content>merican <styled-content style="fixed-case">A</styled-content>ssociation of <styled-content style="fixed-case">C</styled-content>linical <styled-content style="fixed-case">E</styled-content>ndocrinologists; <styled-content style="fixed-case">ADA</styled-content>, <styled-content style="fixed-case">A</styled-content>merican <styled-content style="fixed-case">D</styled-content>iabetes <styled-content style="fixed-case">A</styled-content>ssociation; <styled-content style="fixed-case">HbA1c</styled-content>, glycated haemoglobin; <styled-content style="fixed-case">OR</styled-content>, odds ratio.</p></caption><graphic id="nlm-graphic-5" xlink:href="DOM-18-1191-g002"/></fig></sec><sec id="dom12736-sec-0024"><label>3.4.5</label><title>Percentage of subjects achieving composite endpoints</title><p id="dom12736-para-0037">After 26&#x02009;weeks, a significantly higher proportion of subjects achieved the composite endpoints with liraglutide than with sitagliptin. Proportions of subjects achieving the composite endpoint of HbA1c reduction &#x02265;1.0% and no weight gain were<bold>:</bold> 52.8% versus 29.1% (liraglutide vs. sitagliptin), OR: 2.85 (95% CI 1.82&#x02010;4.47, p&#x02009;&#x0003c;&#x02009;0.0001). Proportions of subjects achieving the composite endpoint of HbA1c &#x0003c;7.0% and no weight gain were: 48.3% versus 24.2% (liraglutide vs. sitagliptin), OR: 3.40 (95% CI 2.11&#x02013;5.49, p&#x02009;&#x0003c;&#x02009;0.0001). Proportions of subjects achieving the composite endpoint of HbA1c &#x0003c;7.0%, no weight gain and SBP &#x0003c;140&#x02009;mm Hg were: 44.9% versus 19.2% (liraglutide vs. sitagliptin), OR: 3.88 (95% CI 2.36&#x02010;6.39, p&#x02009;&#x0003c;&#x02009;0.0001) (Figure S2).</p></sec></sec><sec id="dom12736-sec-0025"><label>3.5</label><title>Safety endpoints</title><p id="dom12736-para-0038">As expected, subjects who discontinued sitagliptin and switched to liraglutide experienced more AEs than those continuing on sitagliptin (68.8% vs. 56.9%; Table <xref rid="dom12736-tbl-0001" ref-type="table-wrap">1</xref>). Incidence of serious AEs was low in both groups: eight events per group [six subjects taking liraglutide (3.0%) and seven subjects taking sitagliptin (3.4%)]. There was one non&#x02010;treatment&#x02010;emergent death in the liraglutide group, judged &#x02018;unlikely related&#x02018; to liraglutide by the investigator.</p><p id="dom12736-para-0039">The most common TEAEs considered possibly/probably related to liraglutide were GI (nausea and diarrhoea) and metabolism and nutrition disorders (decreased appetite), particularly during the first 4&#x02009;weeks of treatment. The proportion of subjects with GI AEs was higher with liraglutide (40.1%) than sitagliptin (20.6%). Nausea (21.8% vs. 7.8%, Figure S3), vomiting (7.4% vs. 4.9%), diarrhoea (16.3% vs. 9.3%) and decreased appetite (8.9% vs. 3.4%) were all more frequent with liraglutide than with sitagliptin (see Figure S4 for incidence of All GI AEs). There was no incidence of pancreatitis or malignant neoplasms reported with liraglutide during the trial, but there were two malignant neoplasms in the sitagliptin group (bladder cancer and squamous cell carcinoma of skin, both assessed by the investigator as &#x02018;unlikely unrelated&#x02019; to trial product). The proportion of subjects with AEs leading to premature treatment discontinuation was higher with liraglutide than with sitagliptin, mainly driven by GI AEs (treatment discontinuation due to AEs: 6.4% (4.5% GI AEs) for liraglutide and 2.5% (0% GI AEs) for sitagliptin).</p><p id="dom12736-para-0040">No severe hypoglycaemic episodes were reported. Confirmed hypoglycaemic episodes were rare: three episodes for three subjects with sitagliptin (1.5%), of whom two subjects were on rescue therapy with insulin and sulphonylurea, respectively.</p><p id="dom12736-para-0041">Pulse rate increased by 2.57&#x02009;beats per minute (bpm) for liraglutide and decreased by &#x02212;0.10&#x02009;bpm for sitagliptin: ETD 2.67&#x02009;bpm (95% CI 1.07&#x02010;4.27; p&#x02009;=&#x02009;0.0011).</p><p id="dom12736-para-0042">Increases were observed in serum amylase for both liraglutide (8%) and sitagliptin (4%); the difference between treatment groups was not statistically significant: estimated treatment ratio (ETR): 1.03 (95% CI 0.98&#x02010;1.09; p&#x02009;=&#x02009;0.2363). A greater increase was observed in serum lipase for liraglutide (11%) versus sitagliptin (1%), a statistically significant difference [ETR 1.10 (95% CI 1.00&#x02010;1.21; p&#x02009;=&#x02009;0.0392)].</p></sec></sec><sec id="dom12736-sec-0026"><label>4</label><title>CONCLUSIONS</title><p id="dom12736-para-0043">The present study showed that, in subjects with T2D with elevated HbA1c on dual combination treatment with sitagliptin&#x02009;+&#x02009;metformin, switching from sitagliptin to liraglutide was associated with improved glycaemic control and weight reduction compared with continued sitagliptin. During the trial, subjects who remained on sitagliptin tended to improve in these outcomes, but switching to liraglutide was significantly more efficacious. Improved blood glucose control with liraglutide was achieved with acceptable tolerability; hypoglycaemia was very rare, and other clinical endpoints such as blood pressure and lipids showed favourable or clinically insignificant changes.</p><p id="dom12736-para-0044">These results also emphasize the importance of generally differentiating between the DPP&#x02010;4i and GLP&#x02010;1RA classes, since further improvement in glycaemic control can be achieved by substituting sitagliptin for liraglutide, as was originally suggested by the LIRA&#x02010;DPP&#x02010;4 main and extension trials.<xref rid="dom12736-bib-0008" ref-type="ref">8</xref>, <xref rid="dom12736-bib-0010" ref-type="ref">10</xref>
</p><p id="dom12736-para-0045">When comparing baseline characteristics and findings of the LIRA&#x02010;DPP&#x02010;4 trial with the present trial (there was a lower HbA1c at baseline in the LIRA&#x02010;DPP&#x02010;4 trial of 7.6%) when all subjects, regardless of their HbA1C, were switched from sitagliptin to liraglutide, HbA1c was then further reduced by &#x02212;0.45% with liraglutide 1.8&#x02009;mg after 26&#x02009;weeks. In the present trial, baseline HbA1c was higher (8.3%) and change from baseline with liraglutide 1.8&#x02009;mg was &#x02212;1.14%, with a corresponding ETD between liraglutide 1.8&#x02009;mg and sitagliptin of &#x02212;0.61%. The difference in change from baseline is probably related to differences in HbA1c at time of switching.</p><p id="dom12736-para-0046">As subjects in the sitagliptin arm were continuing current therapy, the fairly similar overall proportions of subjects reporting AEs and severe AEs with liraglutide and sitagliptin were reassuring. AEs in the liraglutide group were mainly driven by GI AEs, which also were the main reason for a higher rate of subjects discontinuing the trial drug because of AEs.</p><p id="dom12736-para-0047">It is important to consider that subjects in the sitagliptin&#x02009;+&#x02009;metformin arm were continuing on therapy that they were accustomed to. Also, subjects who switched from sitagliptin to liraglutide had already been used to <italic>some</italic> level of therapy that mediates its effect via the incretin pathway (albeit different treatment classes); therefore, the level of GI side effects might not be representative for a patient commencing liraglutide without previously having experienced sitagliptin treatment. However, in the original LIRA&#x02010;DPP&#x02010;4 study, rates of GI AEs were similar to those in this trial.<xref rid="dom12736-bib-0008" ref-type="ref">8</xref>
</p><p id="dom12736-para-0048">It is known that up to 25% of subjects with T2D have elevated amylase or lipase levels,<xref rid="dom12736-bib-0014" ref-type="ref">14</xref> and lipase and amylase increases have been observed previously after initiation of treatment with several DPP&#x02010;4is and GLP&#x02010;1RAs, including liraglutide.<xref rid="dom12736-bib-0015" ref-type="ref">15</xref>, <xref rid="dom12736-bib-0016" ref-type="ref">16</xref>, <xref rid="dom12736-bib-0017" ref-type="ref">17</xref> In this trial, lipase changes were observed among subjects continuing on pretrial sitagliptin and those switching to liraglutide. A non&#x02010;significant, minor increase in amylase was also observed in both treatment groups. Similar increases in pulse rate with liraglutide, as reported in this trial, have been previously reported.<xref rid="dom12736-bib-0018" ref-type="ref">18</xref> While no AEs related to elevated pulse rate were reported during the trial, the clinical relevance is currently unknown. However, a cardiovascular outcomes trial (LEADER) to determine long&#x02010;term effects of liraglutide on cardiovascular safety in subjects with T2D has recently been completed and showed that liraglutide significantly reduces the risk of major adverse cardiovascular events.<xref rid="dom12736-bib-0019" ref-type="ref">19</xref>
</p><p id="dom12736-para-0049">This is the first trial with a robust randomized, double&#x02010;blind, double&#x02010;dummy, active&#x02010;controlled design to address the question of whether patients with T2D insufficiently controlled on sitagliptin therapy might obtain improved glycaemic control by switching to liraglutide. Switching from sitagliptin to a GLP&#x02010;1RA has been previously assessed, but these trials have been either extension or open&#x02010;label studies, or not designed as confirmatory trials.<xref rid="dom12736-bib-0011" ref-type="ref">11</xref>, <xref rid="dom12736-bib-0020" ref-type="ref">20</xref>, <xref rid="dom12736-bib-0021" ref-type="ref">21</xref> In the 26&#x02010;week, open&#x02010;label extension to the DURATION&#x02010;2 trial, switching from sitagliptin to once&#x02010;weekly exenatide resulted in significantly improved glycaemic control, as well as weight loss, but to a lesser extent than in the current LIRA&#x02010;SWITCH trial.<xref rid="dom12736-bib-0020" ref-type="ref">20</xref> The reduction in HbA1c and body weight in the DURATION&#x02010;2 trial was consistent with results from a non&#x02010;inferiority trial,<xref rid="dom12736-bib-0021" ref-type="ref">21</xref> in which switching from sitagliptin to twice&#x02010;daily exenatide significantly reduced HbA1c; however, non&#x02010;inferiority was not met when comparing HbA1c reduction in the switch arm of this trial with HbA1c reduction in the add&#x02010;on exenatide arm.</p><p id="dom12736-para-0050">Typical strategies for patients failing on OADs include adding a third OAD or adding insulin therapy.<xref rid="dom12736-bib-0002" ref-type="ref">2</xref> Each of these choices will increase regimen complexity and may compromise tolerability. Therefore, switching from a DPP&#x02010;4i to a GLP&#x02010;1RA could be seen as a pragmatic and attractive option, which offers the benefit of allowing the patient to remain on dual therapy while still achieving a superior improvement in glycaemic control and weight loss. Thus, the effects of switching from sitagliptin to liraglutide on glycaemic control and body weight in this trial suggest that moving horizontally in the treatment algorithm<xref rid="dom12736-bib-0001" ref-type="ref">1</xref>, <xref rid="dom12736-bib-0002" ref-type="ref">2</xref> is a relevant option that may safely be considered for subjects insufficiently controlled on sitagliptin.</p><p id="dom12736-para-0051">The benefit observed here, when switching from a DPP&#x02010;4i to liraglutide, may not necessarily be transferred to other GLP&#x02010;1RAs, given that GLP&#x02010;1RAs have shown different efficacy outcomes regarding glycaemic control and change in body weight.<xref rid="dom12736-bib-0015" ref-type="ref">15</xref>, <xref rid="dom12736-bib-0022" ref-type="ref">22</xref>, <xref rid="dom12736-bib-0023" ref-type="ref">23</xref>, <xref rid="dom12736-bib-0024" ref-type="ref">24</xref>, <xref rid="dom12736-bib-0025" ref-type="ref">25</xref> It also follows that this trial may not necessarily be extrapolated to cover switching from any DPP&#x02010;4i to liraglutide.</p><p id="dom12736-para-0052">In conclusion, results from the LIRA&#x02010;SWITCH trial confirm that patients with T2D insufficiently controlled with sitagliptin who switch to liraglutide can obtain clinically relevant reductions in glycaemia and body weight, without compromising safety. This switch provides a clinically relevant option for improved T2D management while allowing patients to remain on dual therapy.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="dom12736-supitem-0001"><caption><p id="dom12736-para-0001">
<bold>Appendix S1.</bold> Exclusion criteria.</p><p id="dom12736-para-0002">
<bold>Appendix S2.</bold> Rescue treatment criteria.</p><p id="dom12736-para-0003">
<bold>Appendix S3.</bold> Criteria for discontinuation of trial products or withdrawal.</p><p id="dom12736-para-0004">
<bold>Appendix S4.</bold> Protocol amendments.</p><p id="dom12736-para-0005">
<bold>Appendix S5.</bold> Method of assigning subjects to treatment groups.</p><p id="dom12736-para-0006">
<bold>Appendix S6.</bold> List of participating investigators (numbers refer to total number of sites).</p></caption><media xlink:href="DOM-18-1191-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom12736-supitem-0002"><caption><p id="dom12736-para-0007">
<bold>Figure S1.</bold> Difference in concentration (mmol/<styled-content style="fixed-case">L</styled-content>) of fasting blood lipids after 26&#x02009;weeks of treatment between liraglutide and sitagliptin shown as the treatment ratio liraglutide/sitagliptin at week 26.</p><p id="dom12736-para-0008">
<bold>Figure S2.</bold> Subjects meeting composite endpoints after 26&#x02009;weeks of treatment.</p><p id="dom12736-para-0009">
<bold>Figure S3.</bold> Percentage of subjects experiencing nausea by day over the course of the study.</p><p id="dom12736-para-0010">
<bold>Figure S4.</bold> Percentage of subjects experiencing gastrointestinal adverse events by day over the course of the study.</p></caption><media xlink:href="DOM-18-1191-s002.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="dom12736-sec-0027"><title>ACKNOWLEDGMENTS</title><p id="dom12736-para-0053">Funding was provided by Novo Nordisk. Writing assistance was provided by Nathan Ley, PhD, of Watermeadow Medical, UK, funded by Novo Nordisk. The authors thank the patients, investigators, and staff for their participation. For a list of participating investigators, see Appendix S6. <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> identifier: NCT01907854.</p><sec id="dom12736-sec-0028"><title>Funding information</title><p id="dom12736-para-0054">Funding was provided by Novo Nordisk.</p></sec><sec id="dom12736-sec-0029"><title>Conflict of interest</title><p id="dom12736-para-0055">T.S.B. received research support from Abbott, ACON, Bayer, BD, Boehringer Ingelheim, Bristol&#x02010;Myers Squibb, Companion Medical, Dexcom, Elcelyx, Insulet, Janssen, Lexicon, Lifescan, Lilly, Medtronic, Merck, Novo Nordisk, Sanofi, and Versartis; received consulting honoraria from AstraZeneca, Bayer, BD, Lilly, Medtronic, Novo Nordisk, Sanofi; and received speaking honoraria from Abbott, Insulet, Novo Nordisk, and Sanofi. F.J.T. is a member of advisory boards for AstraZeneca, Boehringer Ingelheim, Bristol&#x02010;Myers Squibb, Eli Lilly, GlaxoSmithKline, Hoffman LaRoche, Merck, Merck Sharp &#x00026; Dohme, Novartis, Novo Nordisk and Sanofi; is a consultant for AstraZeneca, Boehringer Ingelheim, Bristol&#x02010;Myers Squibb, Eli Lilly, GlaxoSmithKline, Hoffman LaRoche, Merck, Merck Sharp &#x00026; Dohme, Novartis, Novo Nordisk, and Sanofi; and received research support from AstraZeneca, Eli Lilly, Hoffman LaRoche, Merck, Merck Sharp &#x00026; Dohme, Novartis, Novo Nordisk, and Sanofi. G.M.T. is a member of advisory boards for Amgen, Merck and Eli Lilly; and received speaking honoraria from Amgen, AstraZeneca, Eli Lilly &#x00026; Novo Nordisk. A.B.T. and M.S.K. are employees of Novo Nordisk A/S. R.T., P.V.R. and M.M. have no conflicts to declare.</p></sec><sec id="dom12736-sec-0030"><title>Author contributions</title><p id="dom12736-para-0056">M.S.K. and A.B.T. were the medical directors for the trial. They and their teams designed the trial, developed the protocol and were responsible for trial conduct, data analysis and presentation. T.S.B., R.T., F.J.T., P.V.R., G.M.T., A.B.T., M.S.K. and M.M. contributed to data acquisition, analysis, interpretation and writing the manuscript. All authors contributed to revisions and approved the final version. T.S.B. is the guarantor and had full access to all the study data and takes responsibility for integrity of the data and accuracy of the analysis.</p></sec></ack><ref-list content-type="cited-references" id="dom12736-bibl-0001"><title>REFERENCES</title><ref id="dom12736-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="dom12736-cit-0001">
<string-name>
<surname>Inzucchi</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Bergenstal</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Buse</surname>
<given-names>JB</given-names>
</string-name>, et&#x02009;al. <article-title>Management of hyperglycemia in type 2 diabetes: a patient&#x02010;centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)</article-title>. <source>Diabetes Care</source>. <year>2012</year>;<volume>35</volume>:<fpage>1364</fpage>&#x02013;<lpage>1379</lpage>.<pub-id pub-id-type="pmid">22517736</pub-id></mixed-citation></ref><ref id="dom12736-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="dom12736-cit-0002">
<string-name>
<surname>Inzucchi</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Bergenstal</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Buse</surname>
<given-names>JB</given-names>
</string-name>, et&#x02009;al. <article-title>Management of hyperglycaemia in type 2 diabetes, 2015: a patient&#x02010;centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes</article-title>. <source>Diabetologia</source>. <year>2015</year>;<volume>58</volume>:<fpage>429</fpage>&#x02013;<lpage>442</lpage>.<pub-id pub-id-type="pmid">25583541</pub-id></mixed-citation></ref><ref id="dom12736-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="dom12736-cit-0003">
<string-name>
<surname>Flint</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kapitza</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Hindsberger</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Zdravkovic</surname>
<given-names>M</given-names>
</string-name>. <article-title>The once&#x02010;daily human glucagon&#x02010;like peptide&#x02010;1 (GLP&#x02010;1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients</article-title>. <source>Adv Ther</source>. <year>2011</year>;<volume>28</volume>:<fpage>213</fpage>&#x02013;<lpage>226</lpage>.<pub-id pub-id-type="pmid">21340616</pub-id></mixed-citation></ref><ref id="dom12736-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="dom12736-cit-0004">
<string-name>
<surname>Marre</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Shaw</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Br&#x000e4;ndle</surname>
<given-names>M</given-names>
</string-name>, et&#x02009;al. <article-title>Liraglutide, a once&#x02010;daily human GLP&#x02010;1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD&#x02010;1 SU)</article-title>. <source>Diabet Med</source>. <year>2009</year>;<volume>26</volume>:<fpage>268</fpage>&#x02013;<lpage>278</lpage>.<pub-id pub-id-type="pmid">19317822</pub-id></mixed-citation></ref><ref id="dom12736-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="dom12736-cit-0005">
<string-name>
<surname>Herman</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Stevens</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Van Dyck</surname>
<given-names>K</given-names>
</string-name>, et&#x02009;al. <article-title>Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double&#x02010;blind, placebo&#x02010;controlled studies with single oral doses</article-title>. <source>Clin Pharmacol Ther</source>. <year>2005</year>;<volume>78</volume>:<fpage>675</fpage>&#x02013;<lpage>688</lpage>.<pub-id pub-id-type="pmid">16338283</pub-id></mixed-citation></ref><ref id="dom12736-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="dom12736-cit-0006">
<string-name>
<surname>Aschner</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kipnes</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Lunceford</surname>
<given-names>JK</given-names>
</string-name>, et&#x02009;al. <article-title>Effect of the dipeptidyl peptidase&#x02010;4 inhibitor sitagliptin as monotherapy on glycaemic control in patients with type 2 diabetes</article-title>. <source>Diabetes Care</source>. <year>2006</year>;<volume>29</volume>:<fpage>2632</fpage>&#x02013;<lpage>2637</lpage>.<pub-id pub-id-type="pmid">17130196</pub-id></mixed-citation></ref><ref id="dom12736-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="dom12736-cit-0007">
<string-name>
<surname>Nauck</surname>
<given-names>M</given-names>
</string-name>. <article-title>Incretin therapies&#x02013;highlighting common features and differences in the modes of action of GLP&#x02010;1 receptor agonists and DPP&#x02010;4 inhibitors</article-title>. <source>Diabetes Obes Metab</source>. <year>2016</year>;<volume>18</volume>:<fpage>203</fpage>&#x02013;<lpage>216</lpage>.<pub-id pub-id-type="pmid">26489970</pub-id></mixed-citation></ref><ref id="dom12736-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="dom12736-cit-0008">
<string-name>
<surname>Pratley</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>Nauck</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bailey</surname>
<given-names>T</given-names>
</string-name>, et&#x02009;al. <article-title>Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26&#x02010;week, randomised, parallel&#x02010;group, open&#x02010;label trial</article-title>. <source>Lancet</source>. <year>2010</year>;<volume>375</volume>:<fpage>1447</fpage>&#x02013;<lpage>1456</lpage>.<pub-id pub-id-type="pmid">20417856</pub-id></mixed-citation></ref><ref id="dom12736-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="dom12736-cit-0009">
<string-name>
<surname>Nauck</surname>
<given-names>MA</given-names>
</string-name>. <article-title>Incretin based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications</article-title>. <source>Am J Med</source>. <year>2011</year>;<volume>124</volume>:<fpage>S3</fpage>&#x02013;<lpage>S18</lpage>.<pub-id pub-id-type="pmid">21194578</pub-id></mixed-citation></ref><ref id="dom12736-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="dom12736-cit-0010">
<string-name>
<surname>Pratley</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Nauck</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bailey</surname>
<given-names>T</given-names>
</string-name>, et&#x02009;al. <article-title>One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel&#x02010;group, open&#x02010;label trial</article-title>. <source>Int J Clin Pract</source>. <year>2011</year>;<volume>65</volume>:<fpage>397</fpage>&#x02013;<lpage>407</lpage>.<pub-id pub-id-type="pmid">21355967</pub-id></mixed-citation></ref><ref id="dom12736-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="dom12736-cit-0011">
<string-name>
<surname>Pratley</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>Nauck</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Bailey</surname>
<given-names>T</given-names>
</string-name>, et&#x02009;al. <article-title>Efficacy and safety of switching from the DPP&#x02010;4 inhibitor sitagliptin to the human GLP&#x02010;1 analog liraglutide after 52 weeks in metformin&#x02010;treated patients with type 2 diabetes: a randomized, open&#x02010;label trial</article-title>. <source>Diabetes Care</source>. <year>2012</year>;<volume>35</volume>:<fpage>1986</fpage>&#x02013;<lpage>1993</lpage>.<pub-id pub-id-type="pmid">22851600</pub-id></mixed-citation></ref><ref id="dom12736-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="dom12736-cit-0012">
<collab collab-type="authors" id="dom12736-gp-0001">World Medical Association</collab>
. <article-title>World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects</article-title>. <source>JAMA</source>. <year>2013</year>;<volume>310</volume>:<fpage>2191</fpage>&#x02013;<lpage>2194</lpage>.<pub-id pub-id-type="pmid">24141714</pub-id></mixed-citation></ref><ref id="dom12736-bib-0013"><label>13</label><mixed-citation publication-type="miscellaneous" id="dom12736-cit-0013">
<collab collab-type="authors" id="dom12736-gp-0002">International Conference on Harmonisation</collab>
. <article-title>ICH harmonised tripartite guideline. Good clinical practice</article-title>
<year>1996</year>
<ext-link ext-link-type="uri" xlink:href="http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf">http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf</ext-link>. Accessed August 10, 2016.</mixed-citation></ref><ref id="dom12736-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="dom12736-cit-0014">
<string-name>
<surname>Steinberg</surname>
<given-names>WM</given-names>
</string-name>, <string-name>
<surname>Nauck</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Zinman</surname>
<given-names>B</given-names>
</string-name>, et&#x02009;al. <article-title>LEADER 3&#x02010;&#x02010;lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial</article-title>. <source>Pancreas</source>. <year>2014</year>;<volume>43</volume>:<fpage>1223</fpage>&#x02013;<lpage>1231</lpage>.<pub-id pub-id-type="pmid">25275271</pub-id></mixed-citation></ref><ref id="dom12736-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="dom12736-cit-0015">
<string-name>
<surname>Dungan</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Povedano</surname>
<given-names>ST</given-names>
</string-name>, <string-name>
<surname>Forst</surname>
<given-names>T</given-names>
</string-name>, et&#x02009;al. <article-title>Once&#x02010;weekly dulaglutide versus once&#x02010;daily liraglutide in metformin&#x02010;treated patients with type 2 diabetes (AWARD&#x02010;6): a randomised, open&#x02010;label, phase 3, non&#x02010;inferiority trial</article-title>. <source>Lancet</source>. <year>2014</year>;<volume>384</volume>:<fpage>1349</fpage>&#x02013;<lpage>1357</lpage>.<pub-id pub-id-type="pmid">25018121</pub-id></mixed-citation></ref><ref id="dom12736-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="dom12736-cit-0016">
<string-name>
<surname>Lando</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Alattar</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Dua</surname>
<given-names>AP</given-names>
</string-name>. <article-title>Elevated amylase and lipase levels in patients using glucagonlike peptide&#x02010;1 receptor agonists or dipeptidyl&#x02010;peptidase&#x02010;4 inhibitors in the outpatient setting</article-title>. <source>Endocr Pract</source>. <year>2012</year>;<volume>18</volume>:<fpage>472</fpage>&#x02013;<lpage>477</lpage>.<pub-id pub-id-type="pmid">22440997</pub-id></mixed-citation></ref><ref id="dom12736-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="dom12736-cit-0017">
<string-name>
<surname>Tokuyama</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kawamura</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Fujimoto</surname>
<given-names>M</given-names>
</string-name>, et&#x02009;al. <article-title>A low&#x02010;grade increase of serum pancreatic exocrine enzyme levels by dipeptidyl peptidase&#x02010;4 inhibitor in patients with type 2 diabetes</article-title>. <source>Diabetes Res Clin Pract</source>. <year>2013</year>;<volume>100</volume>:<fpage>e66</fpage>&#x02013;<lpage>e69</lpage>.<pub-id pub-id-type="pmid">23618553</pub-id></mixed-citation></ref><ref id="dom12736-bib-0018"><label>18</label><mixed-citation publication-type="miscellaneous" id="dom12736-cit-0018">
<collab collab-type="authors" id="dom12736-gp-0003">Novo Nordisk A/S</collab>
. <article-title>Victoza&#x02013;European summary of product characteristics</article-title>. <year>2015</year>
<ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001026/WC500050017.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_&#x02010;_Product_Information/human/001026/WC500050017.pdf</ext-link>. Accessed August 10, 2016.</mixed-citation></ref><ref id="dom12736-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="dom12736-cit-0019">
<string-name>
<surname>Marso</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Daniels</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Brown&#x02010;Frandsen</surname>
<given-names>K</given-names>
</string-name>, et&#x02009;al. Liraglutide and cardiovascular outcomes in type 2 diabetes. <source>New Engl J Med</source>. <year>2016</year>;<volume>375</volume>:<fpage>311</fpage>&#x02013;<lpage>322</lpage>.<pub-id pub-id-type="pmid">27295427</pub-id></mixed-citation></ref><ref id="dom12736-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="dom12736-cit-0020">
<string-name>
<surname>Wysham</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bergenstal</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Malloy</surname>
<given-names>J</given-names>
</string-name>, et&#x02009;al. <article-title>DURATION&#x02010;2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once&#x02010;weekly exenatide</article-title>. <source>Diabet Med</source>. <year>2011</year>;<volume>28</volume>:<fpage>705</fpage>&#x02013;<lpage>714</lpage>.<pub-id pub-id-type="pmid">21434995</pub-id></mixed-citation></ref><ref id="dom12736-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="dom12736-cit-0021">
<string-name>
<surname>Violante</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Oliveira</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Yoon</surname>
<given-names>KH</given-names>
</string-name>, et&#x02009;al. <article-title>A randomized non&#x02010;inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin</article-title>. <source>Diabet Med</source>. <year>2012</year>;<volume>29</volume>:<fpage>e417</fpage>&#x02013;<lpage>e424</lpage>.<pub-id pub-id-type="pmid">22375612</pub-id></mixed-citation></ref><ref id="dom12736-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="dom12736-cit-0022">
<string-name>
<surname>Pratley</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>Nauck</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Barnett</surname>
<given-names>AH</given-names>
</string-name>, et&#x02009;al. <article-title>Once&#x02010;weekly albiglutide versus once&#x02010;daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open&#x02010;label, multicentre, non&#x02010;inferiority phase 3 study</article-title>. <source>Lancet Diabetes Endocrinol</source>. <year>2014</year>;<volume>2</volume>:<fpage>289</fpage>&#x02013;<lpage>297</lpage>.<pub-id pub-id-type="pmid">24703047</pub-id></mixed-citation></ref><ref id="dom12736-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="dom12736-cit-0023">
<string-name>
<surname>Buse</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Rosenstock</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sesti</surname>
<given-names>G</given-names>
</string-name>, et&#x02009;al. <article-title>Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26&#x02010;week randomised, parallel&#x02010;group, multinational, open&#x02010;label trial (LEAD&#x02010;6)</article-title>. <source>Lancet</source>. <year>2009</year>;<volume>374</volume>:<fpage>39</fpage>&#x02013;<lpage>47</lpage>.<pub-id pub-id-type="pmid">19515413</pub-id></mixed-citation></ref><ref id="dom12736-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="dom12736-cit-0024">
<string-name>
<surname>Buse</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Nauck</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Forst</surname>
<given-names>T</given-names>
</string-name>, et&#x02009;al. <article-title>Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION&#x02010;6): a randomised, open&#x02010;label study</article-title>. <source>Lancet</source>. <year>2013</year>;<volume>381</volume>:<fpage>117</fpage>&#x02013;<lpage>124</lpage>.<pub-id pub-id-type="pmid">23141817</pub-id></mixed-citation></ref><ref id="dom12736-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="dom12736-cit-0025">
<string-name>
<surname>Nauck</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rizzo</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pirags</surname>
<given-names>V</given-names>
</string-name>, et&#x02009;al. <article-title>Once&#x02010;daily liraglutide vs. lixisenatide as add&#x02010;on to metformin in type 2 diabetes: a 26&#x02010;week randomised controlled clinical trial (Abstract 75)</article-title>. <source>Diabetologia</source>. <year>2015</year>;<volume>58</volume>(<issue>suppl 1</issue>):<fpage>1</fpage>&#x02013;<lpage>607</lpage>.</mixed-citation></ref></ref-list></back></article>